Evidence map›Paper›PMID 30656565›Full record

ArticleClinical pharmacokinetics2019

Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations.

Pieter J Colin, Karel Allegaert, Alison H Thomson, Daan J Touw, Michael Dolton, Matthijs de Hoog, Jason A Roberts, Eyob D Adane, Masato Yamamoto, Dolores Santos-Buelga and 7 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 4 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Vancomycin AUCAntibiotics (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. State of Vancomycin Dosing in Neonates: An Overview.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 9 countries.

Pieter J ColinDepartment of Anesthesiology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB, Groningen, The Netherlands. p.j.colin@umcg.nl.ORCID 0000-0003-3616-5539
Karel AllegaertPediatric Intensive Care, Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands.
Alison H ThomsonStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Daan J TouwDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Michael DoltonFaculty of Pharmacy, University of Sydney, Sydney, NSW, Australia.
Matthijs de HoogDepartment of Pediatrics, Erasmus University and University Hospital Rotterdam/Sophia Children's Hospital, Rotterdam, The Netherlands.
Jason A RobertsUniversity of Queensland Centre for Clinical Research and School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia.
Eyob D AdaneRaabe College of Pharmacy, Ohio Northern University, Ada, OH, USA.
Masato YamamotoDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Dolores Santos-BuelgaDepartment of Pharmacy and Pharmaceutical Technology, University of Salamanca, Salamanca, Spain.
Ana Martín-SuarezDepartment of Pharmacy and Pharmaceutical Technology, University of Salamanca, Salamanca, Spain.
Nicolas SimonAix-Marseille University, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, CAP, Marseille, France.
Fabio S TacconeDepartment of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Yoke-Lin LoDepartment of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Emilia BarciaDepartment of Pharmaceutics and Food Technology, School of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain.
Michel M R F StruysDepartment of Anesthesiology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB, Groningen, The Netherlands.
Douglas J EleveldDepartment of Anesthesiology, University Medical Center Groningen, University of Groningen, P.O. Box 30001, 9700 RB, Groningen, The Netherlands.
University Medical Center Groningen · NLErasmus MC - Sophia Children’s Hospital · NLUniversidad de Salamanca · ESInserm · FRNagoya University Hospital · JPOhio Northern University · USThe University of Queensland · AUThe University of Sydney · AUUniversidad Complutense de Madrid · ESUniversité Libre de Bruxelles · BEUniversity of Malaya · MYUniversity of Strathclyde · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesUncertainty exists regarding the optimal dosing regimen for vancomycin in different patient populations, leading to a plethora of subgroup-specific pharmacokinetic models and derived dosing regimens. We aimed to investigate whether a single model for vancomycin could be developed based on a broad dataset covering the extremes of patient characteristics. Furthermore, as a benchmark for current dosing recommendations, we evaluated and optimised the expected vancomycin exposure throughout life and for specific patient subgroups.

methodsA pooled population-pharmacokinetic model was built in NONMEM based on data from 14 different studies in different patient populations. Steady-state exposure was simulated and compared across patient subgroups for two US Food and Drug Administration/European Medicines Agency-approved drug labels and optimised doses were derived.

resultsThe final model uses postmenstrual age, weight and serum creatinine as covariates. A 35-year-old, 70-kg patient with a serum creatinine level of 0.83 mg dL

conclusionsA population model was developed that is useful for further development of age and kidney function-stratified dosing regimens of vancomycin and for individualisation of treatment through therapeutic drug monitoring and Bayesian forecasting.

Indexed as

Models, BiologicalAdultAgingAnti-Bacterial AgentsArea Under CurveCreatinineDrug MonitoringFemaleHumansMaleMiddle AgedPractice Guidelines as TopicVancomycinAnti-Bacterial AgentsCreatinineVancomycin

Identifiers

PMID30656565
OpenAlexW2909880112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.